+

WO2005100998A3 - Membrane markers for use in cancer diagnosis and therapy - Google Patents

Membrane markers for use in cancer diagnosis and therapy Download PDF

Info

Publication number
WO2005100998A3
WO2005100998A3 PCT/EP2005/004153 EP2005004153W WO2005100998A3 WO 2005100998 A3 WO2005100998 A3 WO 2005100998A3 EP 2005004153 W EP2005004153 W EP 2005004153W WO 2005100998 A3 WO2005100998 A3 WO 2005100998A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
diagnosis
agents
relates
membrane proteins
Prior art date
Application number
PCT/EP2005/004153
Other languages
German (de)
French (fr)
Other versions
WO2005100998A2 (en
Inventor
Silvia Tortola-Perez
Stephanie Lamer
Steffen Heim
Miriam Fuchs
Thomas Buschmann
Volker Seibert
Nikoleta-Kyriaki Fotiadis
Katrin Stedronsky
Joern Meuer
Kirsten Rothmann-Cosic
Tatiana Ilynia
Lueder Fels
Original Assignee
Europroteome Ag
Silvia Tortola-Perez
Stephanie Lamer
Steffen Heim
Miriam Fuchs
Thomas Buschmann
Volker Seibert
Nikoleta-Kyriaki Fotiadis
Katrin Stedronsky
Joern Meuer
Kirsten Rothmann-Cosic
Tatiana Ilynia
Lueder Fels
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europroteome Ag, Silvia Tortola-Perez, Stephanie Lamer, Steffen Heim, Miriam Fuchs, Thomas Buschmann, Volker Seibert, Nikoleta-Kyriaki Fotiadis, Katrin Stedronsky, Joern Meuer, Kirsten Rothmann-Cosic, Tatiana Ilynia, Lueder Fels filed Critical Europroteome Ag
Publication of WO2005100998A2 publication Critical patent/WO2005100998A2/en
Publication of WO2005100998A3 publication Critical patent/WO2005100998A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to agents and methods for the diagnosis, prognosis and treatment of non-steroid dependent cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding plasma membrane proteins of the invention that are differentially expressed in tumour tissues for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and/or biological activity of such proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and/or biological activity of the proteins plasma membrane proteins of the invention, including using agents identified in screening assays described herein, as well as molecules that are complementary to polynucleotide sequences encoding plasmas membrane proteins of the invention and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.
PCT/EP2005/004153 2004-04-16 2005-04-15 Membrane markers for use in cancer diagnosis and therapy WO2005100998A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090152.2 2004-04-16
EP04090152 2004-04-16

Publications (2)

Publication Number Publication Date
WO2005100998A2 WO2005100998A2 (en) 2005-10-27
WO2005100998A3 true WO2005100998A3 (en) 2008-06-12

Family

ID=34982085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004153 WO2005100998A2 (en) 2004-04-16 2005-04-15 Membrane markers for use in cancer diagnosis and therapy

Country Status (1)

Country Link
WO (1) WO2005100998A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904004B1 (en) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc MODULATORS OF SCARB-1 IN THE TREATMENT OF ACNE OR HYPERSEBORRHEA
GB2442059A (en) * 2006-09-19 2008-03-26 Ist Superiore Sanita Test for cancer of the gastrointestinal tract
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
CN103751771B (en) 2008-08-05 2017-09-08 东丽株式会社 Immune inducing agent
MX2011001445A (en) * 2008-08-05 2011-04-05 Toray Industries Cancer detection method.
PT2532365T (en) 2010-02-04 2016-07-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
AU2011211684B2 (en) * 2010-02-04 2014-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN102822335B (en) 2010-02-04 2015-09-30 东丽株式会社 Cancer treat and/or prevent pharmaceutical composition
CN109925511B (en) * 2010-02-04 2024-03-19 东丽株式会社 Medicine for treating and/or preventing cancer
BR112012018951C8 (en) 2010-02-04 2020-06-23 Toray Industries monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination
ES2618026T3 (en) 2011-08-04 2017-06-20 Toray Industries, Inc. Pharmacological composition for the treatment and / or prevention of cancer
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PL2740795T3 (en) 2011-08-04 2017-04-28 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
MX348578B (en) 2011-08-04 2017-06-20 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer.
PT2741085T (en) 2011-08-04 2017-06-30 Toray Industries Method for detecting pancreatic cancer
JP6015448B2 (en) 2011-08-04 2016-10-26 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
ES2634249T3 (en) 2011-08-04 2017-09-27 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prophylaxis of cancer
CN104114581B (en) 2012-02-21 2018-11-30 东丽株式会社 The treatment of cancer and/or prophylactic compositions
RU2633505C2 (en) 2012-02-21 2017-10-12 Торэй Индастриз, Инк. Pharmaceutical composition for cancer treatment and/or prevention
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
MX357505B (en) 2012-02-21 2018-07-12 Toray Industries Medicinal composition for treating and/or preventing cancer.
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
RU2640245C2 (en) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Pharmaceutical composition for liver cancer treatment and/or prevention
KR101416147B1 (en) 2012-07-18 2014-07-09 국립암센터 Use of ADCY3 for the Diagnosis and Treatment of Gastric Cancer
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
WO2014014082A1 (en) 2012-07-19 2014-01-23 東レ株式会社 Cancer detection method
US20160074428A1 (en) * 2013-05-02 2016-03-17 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of human immunodeficiency virus infection
WO2014186862A1 (en) * 2013-05-20 2014-11-27 Dlvr Therapeutics Inc. Diagnostic method and assay for sr-b1 expressing cancers
CN105452294B (en) 2013-08-09 2019-08-02 东丽株式会社 The treatment of cancer and/or prophylactic compositions
CN105301260A (en) * 2015-11-13 2016-02-03 温州医科大学 Breast cancer marker and treatment target protein zero related (PZR) and use thereof
JP2023523628A (en) 2020-05-01 2023-06-06 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド ILT binding agent and method of use thereof
CN114540504B (en) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 Marker group and system for predicting immune curative effect of lung squamous carcinoma patient

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030108926A1 (en) * 2000-03-15 2003-06-12 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
WO2004005483A2 (en) * 2002-07-10 2004-01-15 Exelixis, Inc. ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015071A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1394182A1 (en) * 2002-07-08 2004-03-03 Europroteome AG Agents and methods for diagnosis and therapy of cancer and cancer risk assessment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells
US20030108926A1 (en) * 2000-03-15 2003-06-12 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
EP1394182A1 (en) * 2002-07-08 2004-03-03 Europroteome AG Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
WO2004005483A2 (en) * 2002-07-10 2004-01-15 Exelixis, Inc. ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015071A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Also Published As

Publication number Publication date
WO2005100998A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
MX2010005651A (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof.
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
GB0418388D0 (en) Cell therapy
MXPA05006034A (en) Replication protein.
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
WO2005089123A3 (en) Therapeutic anti-cancer dna
WO2006105343A3 (en) Dkkl-i splice product modulators for cancer diagnosis and therapy
WO2005072050A9 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC FORM 1205A OF 23-02-2007

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载